Table 1: Expression of CCL26/eotaxin3 in ascites
|
Patient |
CCL26 (pg/ml) |
tumor type |
stage |
Treatment* |
Result surgery |
|
1 |
3,8 |
serous |
3C |
NACT |
complete |
|
2 |
26,4 |
serous |
3C |
primary |
complete |
|
3 |
88,3 |
serous |
4 |
NACT |
incomplete |
|
4 |
4,2 |
serous |
3B |
primary |
optimal |
|
5 |
53,7 |
serous |
3C |
primary |
complete |
|
6 |
84,8 |
serous |
3C |
NACT |
complete |
|
7 |
218,1 |
serous |
3C |
primary |
complete |
|
8 |
9,7 |
serous |
3C |
NACT |
complete |
|
9 |
152,0 |
serous |
3C |
NACT |
complete |
|
10 |
0,0 |
serous |
3C |
NACT |
optimal |
|
11 |
0,0 |
serous |
4 |
NACT |
incomplete |
|
12 |
10,0 |
serous |
3C |
NACT |
complete |
|
13 |
0,0 |
serous |
3C |
primary |
optimal |
|
14 |
10,0 |
mucinous |
4 |
primary |
optimal |
|
15 |
4,9 |
serous |
4 |
NACT |
optimal |
|
16 |
61,5 |
clear cell |
3C |
NACT |
complete |
|
17 |
29,3 |
serous |
3C |
primary |
optimal |
*: treatment either primary cytoreduction followed by 6 cycles of advent chemotherapy (carboplatinum + paclitaxel), or neoadjuvant chemotherapy (NACT), followed by interval debulking (cytoreductive surgery), followed by 3 cycles of djuvant chemotherapy
** result surgery: complete: no residual disease; optimal: residual tumor < 1cm; incomplete: residual tumor > 1cm